Literature DB >> 23017732

Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica.

Hiroshi Kuroda1, Kazuo Fujihara, Rina Takano, Yoshiki Takai, Toshiyuki Takahashi, Tatsuro Misu, Ichiro Nakashima, Shigeru Sato, Yasuto Itoyama, Masashi Aoki.   

Abstract

Complement is thought to play a pivotal role in neuromyelitis optica (NMO) pathogenesis. Anaphylatoxins (C3a, C4a, and C5a), produced in complement activation, have proinflammatory potential, and thereby may play an important role. We measured concentrations of anaphylatoxins in CSF and sera, obtained from patients with NMO (n=15), multiple sclerosis (MS) (n=15), and other neurological disease (OND) (n=12), and evaluated their clinical implications. The CSF-C5a levels were elevated significantly in NMO patients, especially in patients with multiple enhanced lesions on MRI. The CSF-C5a levels correlated with the severity of exacerbation. Our results may provide a rationale for anti-complement therapies of NMO.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23017732     DOI: 10.1016/j.jneuroim.2012.09.002

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  14 in total

1.  Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.

Authors:  Julien Ratelade; Nithi Asavapanumas; Alanna M Ritchie; Scott Wemlinger; Jeffrey L Bennett; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

Review 2.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

Review 3.  Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.

Authors:  Vyanka Redenbaugh; Eoin P Flanagan
Journal:  Neurotherapeutics       Date:  2022-03-10       Impact factor: 6.088

Review 4.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 5.  B cells in MS and NMO: pathogenesis and therapy.

Authors:  Markus Krumbholz; Edgar Meinl
Journal:  Semin Immunopathol       Date:  2014-05-16       Impact factor: 9.623

Review 6.  Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics.

Authors:  Laura Cacciaguerra; Paola Tortorella; Maria A Rocca; Massimo Filippi
Journal:  Neurotherapeutics       Date:  2021-04-28       Impact factor: 6.088

7.  Comparison of clinical characteristics between neuromyelitis optica spectrum disorders with and without spinal cord atrophy.

Authors:  Yanqiang Wang; Aimin Wu; Xiaoyu Chen; Lei Zhang; Yinyao Lin; Shaoyang Sun; Wei Cai; Bingjun Zhang; Zhuang Kang; Wei Qiu; Xueqiang Hu; Zhengqi Lu
Journal:  BMC Neurol       Date:  2014-12-20       Impact factor: 2.474

8.  C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.

Authors:  Puay-Wah Phuan; Hua Zhang; Nithi Asavapanumas; Michael Leviten; Arnon Rosenthal; Lukmanee Tradtrantip; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-05-16       Impact factor: 15.887

Review 9.  The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.

Authors:  Michalina Jasiak-Zatonska; Alicja Kalinowska-Lyszczarz; Slawomir Michalak; Wojciech Kozubski
Journal:  Int J Mol Sci       Date:  2016-03-02       Impact factor: 5.923

10.  Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.

Authors:  R Marignier; A Ruiz; S Cavagna; A Nicole; C Watrin; M Touret; S Parrot; G Malleret; C Peyron; C Benetollo; N Auvergnon; S Vukusic; P Giraudon
Journal:  J Neuroinflammation       Date:  2016-05-18       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.